Driehaus Capital Exit — MPWR

Driehaus Capital has fully exited its position in Monolithic Power Systems (MPWR), a semiconductor/power management name with no direct biotech relevance — this exit carries no drug, indication, or pipeline read-through. Worth noting: MPWR remains held by 2 funds in this universe including Eventide Asset Management, though convergence signals carry less weight for non-biotech names within a healthcare-focused mandate.

Unlock full AI analysis — 14-day free trial

Position Trend

Aug 14, 2025

0 funds

Nov 14, 2025

0 funds

Feb 17, 2026

0 funds

May 15, 2026

$63.4M

1 fund

+716% total institutional value over 12 quarters

Short Interest

SI rising 2 periods (+34.8%)

Short Shares

2.32M

Change

+34.8%

Days to Cover

3.3

% of Float

6.3%

Settlement

May 29, 2026

Short interest over 4 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

Driehaus CapitalEXITEDMay 15, 2026

Start free trialfor share counts, dollar values & AI analysis

12 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

BSX1 fund CSTL1 fund P1 fund KLAC1 fund LSCC1 fund PANW1 fund SNDK1 fund NOW1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer